Xavier Leleu

Xavier Leleu

UNVERIFIED PROFILE

Are you Xavier Leleu?   Register this Author

Register author
Xavier Leleu

Xavier Leleu

Publications by authors named "Xavier Leleu"

Are you Xavier Leleu?   Register this Author

100Publications

4403Reads

39Profile Views

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Leukemia 2019 Sep 9;33(9):2324-2330. Epub 2019 Apr 9.

ProfilExpert, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0452-6DOI Listing
September 2019

[Waldenström macroglobulinaemia].

Presse Med 2019 Jul - Aug;48(7-8 Pt 1):832-841. Epub 2019 Aug 20.

CHU de Poitiers, service d'oncohématologie et thérapie cellulaire, 86021 Poitiers. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2019.07.020DOI Listing
August 2019

Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders.

Kidney Int 2019 Jul 15;96(1):94-103. Epub 2019 Mar 15.

Department of Nephrology and Renal Transplantation, Centre Hospitalier Universitaire, Université de Poitiers, Poitiers, France; CNRS UMR 7276, INSERM UMR 1262, Université de Limoges, Limoges, France; INSERM CIC 1402, Centre Hospitalier Universitaire, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.kint.2019.01.027DOI Listing
July 2019

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med 2019 05;380(22):2104-2115

From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La Roche sur Yon (M.T.), CHU de Caen, Caen (M.M.), Department of Clinical Hematology, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris (L.F.), and Department of Hematology, CHU la Miletrie and INSERM CIC 1402, Poitiers (X.L.) - all in France; the Department of Hematology, Mayo Clinic Rochester, Rochester, MN (S.K.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.); Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB (N.B.), and the Division of Medical Oncology, University of Alberta, Edmonton (C.P.V.) - both in Canada; Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom (S.B.); Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia (H.Q.); University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg (H.G.), and the Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (K.W.) - both in Germany; Department of Medicine-Haematology, National University of Ireland, Galway (M.O.); Florida Cancer Specialists and Research Institute, St. Petersburg (J.R.M.); the Department of Hematology-Oncology, Massachusetts General Hospital, Boston (N.R.); Genmab US, Princeton (T.A.), and Janssen Research and Development, Raritan (J.W., R.K.) - both in New Jersey; Janssen Research and Development, Spring House, PA (C.C., C.M.U., M.Q.); Janssen Research and Development, Beerse, Belgium (R.V.R.); and Levine Cancer Institute-Atrium Health, Charlotte, NC (S.Z.U.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1817249
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1817249DOI Listing
May 2019

Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2019 Jan 5;19(1):9-22. Epub 2018 Sep 5.

Department of Hematology, Mayo Clinic, Jacksonville, FL.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183061
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.08.016DOI Listing
January 2019

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

N Engl J Med 2018 11;379(19):1811-1822

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Karol Marcinkowski University of Medical Sciences, Poznań (D.D.), and Silesian Medical University, Katowice (S.G.) - both in Poland; University Hospital, Nantes (P.M.), and Centre Hospitalier Universitaire de Poitiers-La Milétrie, Poitiers (X.L.) - both in France; National Hospital Organization Disaster Medical Center (N.T.) and the Japanese Red Cross Medical Center (K.S.), Tokyo, and Ibaraki Prefectural Central Hospital, Kasama (M.H.) - all in Japan; Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal (R.L.); Heidelberg University Hospital, Heidelberg, Germany (M.S.R.); Dana-Farber Cancer Institute, Boston (P.G.R.); Bristol-Myers Squibb, Princeton, NJ (M.P.M., Y.-M.J., S.G.S., M.R., B.R.); and Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra (IDISNA), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain (J.S.-M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1805762
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1805762DOI Listing
November 2018

Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.

Hematol Oncol Clin North Am 2018 10 27;32(5):753-763. Epub 2018 Jul 27.

Laboratory of Hematology, Biology and Pathology Center, CHU of Lille, Lille, France; INSERM UMR S 1172, Team 4, Cancer Research Institute, Lille, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2018.05.007DOI Listing
October 2018

Age-related health care disparities in multiple myeloma.

Hematol Oncol 2018 Feb 21;36(1):224-231. Epub 2017 Apr 21.

INSERM CIC 1402, CHU, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2422DOI Listing
February 2018

[Circulating exosomal microRNA as biomarkers in mutiple myeloma].

Med Sci (Paris) 2017 Nov 4;33(11):939-941. Epub 2017 Dec 4.

Institut universitaire du cancer Oncopole, avenue Hubert Curien, 31100 Toulouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1051/medsci/20173311008DOI Listing
November 2017

Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia.

Clin Cancer Res 2017 Oct 28;23(20):6325-6335. Epub 2017 Jul 28.

Service d'Hématologie et Thérapie cellulaire, Centre d'Investigation Clinique, Hôpital de la Milétrie, Centre Hospitalier Universitaire de Poitiers, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0007DOI Listing
October 2017

Treatment of Newly Diagnosed Elderly Multiple Myeloma.

Cancer Treat Res 2016;169:123-143

Myeloma Unit, Division of Hematology, University of Torino, Turin, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-40320-5_8
Publisher Site
http://dx.doi.org/10.1007/978-3-319-40320-5_8DOI Listing
June 2017

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

N Engl J Med 2017 04;376(14):1311-1320

From the Institut Universitaire du Cancer de Toulouse-Oncopole (M.A., M.R., C.P., S.R., H.A.-L.) and Service d'Epidémiologie, Centre Hospitalier et Universitaire de Toulouse (V.L.-C.), Toulouse, Hôpital Haut-Lévêque, Bordeaux Pessac (C.H.), Centre Hospitalier et Universitaire la Miletrie, Poitiers (X.L.), Centre Hospitalier Le Bocage, Dijon (D.C.), Centre Hospitalier et Universitaire de Rennes, Rennes (M.E.), Hôpital St.-Louis (B.A., J.P.F.), Centre Hospitalier Universitaire, Hôpital St.-Antoine (L.G.), Institut Curie (C.M.), and Haute Autorité de Santé (J.-L.H.), Paris, Institut d'Hématologie de Basse Normandie, Centre Hospitalier et Universitaire de Caen, Caen (M.M.), Centre Hospitalier et Universitaire Henri Mondor, Creteil (K.B.), Hôpital Claude Huriez, Lille (T.F.), and Hôtel Dieu, Nantes (P.M.) - all in France; Institut Jules Bordet, Brussels (N. Meuleman); and Dana-Farber Cancer Institute, Boston (M.E.M., A.A.Z., E.A.W., N. Munshi, K.C.A., P.G.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201242PMC
April 2017

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

J Clin Oncol 2016 10;34(30):3609-3617

Cyrille Hulin, Bordeaux Hospital University Center, Bourdeaux; Philippe Rodon, Centre Hospitalier de Périgueux, Périgueux; Brigitte Pégourié, Centre Hospitalier Regional Universitaire, Grenoble; Laurent Garderet, Centre Hospitalier Universitaire (CHU) Hôpital St-Antoine, Paris; Isabelle Azais, CHU Institut National de la Santé et de la Recherche Médicale (INSERM); Xavier Leleu, Hôpital de la Milétrie, CHU INSERM, Poitiers; Margaret Macro, CHU de Caen, Caen; Bruno Royer, University Hospital, Amiens; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Andrew Belch, Cross Cancer Institute, Edmonton, Alberta; Chaim Shustik, Royal Victoria Hospital; Richard LeBlanc, Hôpital Maisonneuve-Rosemont, Montreal, Quebec; Kevin Song, Vancouver General Hospital, Vancouver, British Columbia, Canada; Maria Teresa Petrucci, Azienda Policlinico Umberto I, University La Sapienza, Rome, Italy; Ulrich Dührsen, University Hospital of Essen, West German Cancer Center, Essen, Germany; Jin Lu, Peking University Institute of Hematology, People's Hospital, Beijing, China; Hannah Hunter, Derriford Hospital, Plymouth, United Kingdom; Richard Eek, Border Medical Oncology, Wodonga, Victoria, Australia; Heinz Gisslinger, Medizinische Universität Wien, Vienna, Austria; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Cristina Goncalves, Hospital de Santo Antonio-Porto, Porto, Portugal; Ken Romeril, Wellington Hospital, Wellington, New Zealand; Chantal Doyen, Université Catholique de Louvain (UCL), CHU UCL Namur, Yvoir; Fritz Offner, Universitair Ziekenhuis Gent, Ghent, Belgium; Nicolas Leupin, Celgene International, Boudry, Switzerland; Vanessa Houck, Guang Chen, and Annette Ervin-Haynes, Celgene, Summit, NJ; and Meletios A. Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7295DOI Listing
October 2016

Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs.

Am J Hematol 2016 10 14;91(10):E455-6. Epub 2016 Jul 14.

Centre d'investigation Clinique CIC 1408, CHU Saint Etienne, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24454DOI Listing
October 2016

Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.

Cancer Lett 2016 07 19;377(1):17-24. Epub 2016 Apr 19.

Laboratory of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium; Stem Cell Laboratory-Division Clinical Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2016.04.024DOI Listing
July 2016

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

J Clin Oncol 2016 06 25;34(18):2125-32. Epub 2016 Apr 25.

Bruno Royer, Momar Diouf, and Jean Pierre Marolleau, University Hospital, Amiens; Stéphane Minvielle and Philippe Moreau, University Hospital; Stéphane Minvielle, Institut National de la Santé et de la Recherche Médicale U892, Nantes; Murielle Roussel and Hervé Avet-Loiseau, Institute Universitaire du Cancer de Toulouse Oncopole; Hervé Avet-Loiseau, University Hospital, Toulouse; Lionel Karlin, University Hospital, Lyon; Cyrille Hulin, University Hospital, Vandœuvre lès Nancy; Bertrand Arnulf, St Louis University Hospital; Laurent Frenzel, Necker University Hospital; Laurent Garderet, St Antoine University Hospital; Sylvain Choquet, La Pitié University Hospital, Paris; Margaret Macro, University Hospital, Caen; Sylvie Cailleres, General Hospital, Aix en Provence; Annie Brion, University Hospital, Besançon; Sabine Brechignac, University Hospital, Bobigny; Karim Belhadj, University Hospital, Creteil; Marie Lorraine Chretien, University Hospital, Dijon; Marc Wetterwald, General Hospital, Dunkerque; Carine Chaleteix, University Hospital, Clermont-Ferrand; Mourad Tiab, General Hospital, La Roche/Yon; Xavier Leleu, University Hospital, Poitiers; Jean Gabriel Fuzibet, University Department, Nice; Charles Dauriac, University Hospital, Rennes; Luc-Matthieu Forneker, University Hospital, Strasbourg; Lotfi Benboubker, University Hospital, Tours; and Thierry Facon, University Hospital, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1929DOI Listing
June 2016

Global epigenetic regulation of microRNAs in multiple myeloma.

PLoS One 2014 17;9(10):e110973. Epub 2014 Oct 17.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0110973PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201574PMC
December 2015

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Biol Blood Marrow Transplant 2015 Dec 30;21(12):2039-2051. Epub 2015 Sep 30.

University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2015.09.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757494PMC
December 2015

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

J Clin Oncol 2015 Nov 17;33(33):3911-20. Epub 2015 Aug 17.

Brian A. Walker, Eileen M. Boyle, Christopher P. Wardell, Alex Murison, Dil B. Begum, Nasrin M. Dahir, Paula Z. Proszek, David C. Johnson, Martin F. Kaiser, Lorenzo Melchor, Lauren I. Aronson, Charlotte Pawlyn, Fabio Mirabella, John R. Jones, Annamaria Brioli, Faith E. Davies, and Gareth J. Morgan, The Institute of Cancer Research, London; Matthew Scales, The Institute of Cancer Research, Surrey; David A. Cairns, Walter M. Gregory, and Ana Quartilho, University of Leeds; Gordon Cook, St James's University Hospital, Leeds; Mark T. Drayson, University of Birmingham, Birmingham; Nigel Russell, Nottingham University Hospital, Nottingham; Graham H. Jackson, Newcastle University, Newcastle upon Tyne, United Kingdom; Aneta Mikulasova, Masaryk University, Brno, Czech Republic; and Xavier Leleu, Hôpital C. Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2014.59.1503
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.59.1503DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485456PMC
November 2015

Distinctive Patterns of Transthyretin Amyloid in Salivary Tissue: A Clinicopathologic Study of 92 Patients With Amyloid-containing Minor Salivary Gland Biopsies.

Am J Surg Pathol 2015 Aug;39(8):1035-44

Departments of *Pathology †Internal Medicine ‡Biochemistry and Molecular Biology, UF Génopathies §Nephrology ∥Neurology ¶Cardiology #Hematology, CHRU de Lille, Regional Competence Center for Systemic Amyloidosis, and University Lille Nord de France, F-59000, Lille **Laboratoire de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Assistance Publique - Hôpitaux de Paris, Hôpital Bicêtre, CHU Paris Sud, Université Paris Sud, Le Kremlin Bicêtre ††Laboratoire de Biochimie et Génétique Moléculaire, Faculté de Médecine Paris, Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique - Hôpitaux de Paris, Groupe Hospitalier Cochin-Hôtel Dieu; INSERM, Centre de Recherche des Cordeliers, URMS 872, équipe 17 ‡‡Pathology Department, Hôpital Tenon, Assistance Publique - Hôpitaux de Paris, Sorbonne Universités, UPMC Paris 6, Paris, France, F-75020.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000430DOI Listing
August 2015

Bendamustine is effective in T-cell prolymphocytic leukaemia.

Br J Haematol 2015 Mar 15;168(6):916-9. Epub 2014 Oct 15.

Service des Maladies du Sang, Centre Hospitalier Régional et Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13175DOI Listing
March 2015

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.

Genes Chromosomes Cancer 2015 Feb 7;54(2):91-8. Epub 2014 Oct 7.

Division of Molecular Pathology, The Institute of Cancer Research, London, UK; Service des maladies du Sang, Hopital Huriez, Centre Hospitalier Regional Universitaire de Lille, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22222DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310140PMC
February 2015

Pomalidomide for multiple myeloma.

Expert Rev Hematol 2014 Dec 30;7(6):719-31. Epub 2014 Sep 30.

Service des maladies du sang, hôpital Huriez, CHRU de Lille, rue M. Polonovski, 59037 Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.966074DOI Listing
December 2014

MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome.

Br J Haematol 2014 Nov 27;167(4):506-13. Epub 2014 Aug 27.

Service d'Hématologie-Immunologie -Cytogénétique, Centre Hospitalier de Valenciennes, Valenciennes, France; Laboratoire d'Hématologie, Centre de Biologie Pathologie, CHRU, Lille, France; U837, IRCL, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13078DOI Listing
November 2014

Multiple myeloma: the puzzle is finally completed.

Authors:
Xavier Leleu

Lancet Haematol 2014 Oct 22;1(1):e4-5. Epub 2014 Sep 22.

Service des Maladies du Sang, Hôpital Claude Huriez, Lille 59037, France. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523026147000
Publisher Site
http://dx.doi.org/10.1016/S2352-3026(14)70007-9DOI Listing
October 2014

A key to the quest?

Authors:
Xavier Leleu

Blood 2014 Oct;124(14):2162-3

HÔPITAL HURIEZ-CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE LILLE.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2014-08-59
Publisher Site
http://dx.doi.org/10.1182/blood-2014-08-593822DOI Listing
October 2014

Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

J Clin Oncol 2014 Sep 14;32(25):2712-7. Epub 2014 Jul 14.

Murielle Roussel, Valérie Lauwers-Cances, Catherine Gentil, Anne Huynh, Benjamin Hebraud, Jill Corre, and Hervé Avet-Loiseau, Hopitaux de Toulouse; Michel Attal, Institut Claudius Regaud, Toulouse; Nelly Robillard, Philippe Moreau, and Soraya Wuilleme, Hôtel Dieu, Nantes; Cyrille Hulin, Centre Hospitalier Brabois, Nancy; Xavier Leleu and Thierry Facon, Hôpital Claude Huriez, Lille; Lotfi Benboubker, Hôpital Bretonneau, Tours; Gérald Marit, Hôpital Haut-Lévêque, Bordeaux Pessac; Brigitte Pegourie, Hôpital Albert Michallon, Grenoble; Denis Caillot and Marie-Lorraine Chretien, Centre Hospitalier Le Bocage, Dijon; Christophe Fruchart, Centre François Baclesse, Caen; and Anne-Marie Stoppa, Institut Paoli Calmettes, Marseille, France.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/07/10/JCO.2013.54
Web Search
http://200.40.135.66:90/toc/0873/2014/0873-20140901-25-08.pd
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.8164
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.8164DOI Listing
September 2014

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

PLoS One 2013 6;8(11):e79752. Epub 2013 Nov 6.

Department of Lung Cancer Surgery, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, P.R.China ; Stem Cell Laboratory-Division Clinical Hematology, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium ; Department of Hematology and Immunology-Vrije Universiteit Brussel (VUB), Myeloma Center Brussels, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0079752PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819242PMC
August 2014

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

J Clin Oncol 2014 Jul 2;32(20):2173-80. Epub 2014 Jun 2.

Philippe Moreau, University Hospital Hôtel-Dieu; Jean-Luc Harousseau, Centre Rene Gauducheau, Nantes; Michel Attal, Centre Hospitalier Universitaire (CHU) Toulouse; Hervé Avet-Loiseau, CHU Rangueil, Toulouse; Gerald Marit, University Hospital of Bordeaux, Bordeaux; Cyrille Hulin, CHU Nancy, Nancy; Thierry Facon, Hopital Claude Huriez; Xavier Leleu, University Hospital of Lille, Lille; Denis Caillot, CHU Dijon, Dijon; Lotfi Benboubker, Centre Hospitalier Régional Universitaire Tours, Tours; Jean-Yves Mary, University Hospital Paris Saint-Louis, Paris, France; Michele Cavo, Annalisa Pezzi, and Elena Zamagni, Seràgnoli Institute of Hematology, Bologna; Antonio Palumbo, University of Torino, Torino; Maria Teresa Petrucci, Sapienza University of Rome, Rome; Francesca Patriarca, University Hospital, Udine, Italy; Pieter Sonneveld, Erasmus Medical Center, Rotterdam; Bronno van der Holt, Daniel den Hoed Cancer Center at Erasmus Medical Center, Rotterdam; Henk Lokhorst, University Medical Center Utrecht, Utrecht, the Netherlands; Hartmut Goldschmidt, Universitätsklinikum Heidelberg; Kai Neben, University of Heidelberg, Heidelberg, Germany; Laura Rosinol and Joan Bladé, Hospital Clinic, Barcelona; Juan Jose Lahuerta, Hospital Universitario 12 de Octubre, Madrid; Jesus san Miguel, University of Salamanca; Norma Gutierrez, Hospital Universitario de Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.0329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879712PMC
July 2014

Initial treatment of transplant-ineligible patients in multiple myeloma.

Expert Rev Hematol 2014 Feb 28;7(1):67-77. Epub 2013 Nov 28.

Hospital Universitario de Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.864230DOI Listing
February 2014